Ralph A. DeFronzo
University of Texas Health Science Center at San Antonio
Internal medicineEndocrinologyCarbohydrate metabolismChemistryType 2 diabetesInsulin resistanceGlucose uptakeBasal (medicine)PioglitazoneGlucagonGlucose clamp techniqueInsulinImpaired glucose toleranceGlucose tolerance testHyperinsulinemiaType 2 Diabetes MellitusDiabetes mellitusMetabolismMedicineBiology
Publications 860
#1Muhammad A. Abdul-Ghani (University of Texas Health Science Center at San Antonio)H-Index: 54
#2Ralph A. DeFronzo (University of Texas Health Science Center at San Antonio)H-Index: 182
Introduction null Cluster analysis has identified distinct groups of type 2 diabetes (T2D) subjects with distinct metabolic characteristics. Thus, personalizing pharmacologic therapy to individual phenotypic and pathophysiologic characteristics has potential to improve metabolic control and reduce risk of microvascular and macrovascular complications. null Areas covered null The authors review the classification of T2D, genetic markers, pathophysiology and natural history of T2D, the ABCDE appro...
#1Chao Zhang (ZJU: Zhejiang University)H-Index: 123
#2Shuyuan Chen (UTSW: University of Texas Southwestern Medical Center)H-Index: 20
Last. Paul A. Grayburn (Baylor University Medical Center)H-Index: 57
view all 14 authors...
Ultrasound-targeted microbubble destruction (UTMD) mediates gene transfection with high biosafety and thus has been promising toward treatment of type 1 diabetes. However, the potential application of UTMD in type 2 diabetes (T2D) is still limited, due to the lack of systematic design and dynamic monitoring. Herein, an efficient gene delivery system is constructed by plasmid deoxyribonucleic acid (DNA) encoding glucagon-like peptide 1 (GLP-1) in ultrasound-induced microbubbles, toward treatment ...
#1Ralph A. DeFronzo (University of Texas at Austin)H-Index: 182
#2Muhammad A. Abdul-Ghani (University of Texas at Austin)H-Index: 54
Diabetic kidney disease (DKD) accounts for about half of individuals entering end-stage renal disease programs. Patients with DKD frequently have associated microvascular complications and are at very high risk for developing macrovascular complications. Comprehensive treatment involves slowing or preventing the decline in glomerular filtration rate (GFR) and preventing macrovascular and further microvascular complications. Maintaining an A1C
1 CitationsSource
Type 2 diabetes is a cardiorenal metabolic disorder that involves both the microvasculature and the macrovasculature. Hyperglycemia is the major factor responsible for the microvascular complications (i.e., eye, kidney, and nerve damage), whereas insulin resistance and its associated components (e.g., hypertension, dyslipidemia, visceral adiposity, procoagulant state, and endothelial dysfunction) are the major risk factors for the macrovascular complications (i.e., myocardial infarction and stro...
#1Siham Abdelgani (University of Texas Health Science Center at San Antonio)
#2Curtiss Puckett (University of Texas Health Science Center at San Antonio)H-Index: 2
Last. Muhammad A. Abdul-Ghani (University of Texas Health Science Center at San Antonio)H-Index: 54
view all 6 authors...
Aim To identify predictors of response to glucose lowering therapy in patients with new onset diabetes and very high HbA1c (>10%). Research design and methods The study included EDICT participants with initial HbA1c >10% (N = 104). All subjects received a 75-g OGTT before initiation of therapy, and then were randomized to receive: (i) initial Triple Therapy with metformin, pioglitazone, and exenatide versus (ii) stepwise Conventional Therapy with metformin followed by glipizide and then glargine...
Hundreds of thousands of genetic variants have been reported to cause severe monogenic diseases, but the probability that a variant carrier develops the disease (termed penetrance) is unknown for virtually all of them. Additionally, the clinical utility of common polygenetic variation remains uncertain. Using exome sequencing from 77,184 adult individuals (38,618 multi-ancestral individuals from a type 2 diabetes case-control study and 38,566 participants from the UK Biobank, for whom genotype a...
3 CitationsSource
#1Michael EzrokhiH-Index: 8
#2Anthony H. CincottaH-Index: 22
Last. Ralph A. DeFronzoH-Index: 182
view all 9 authors...
#1Maria RayasH-Index: 5
#2Henri HonkaH-Index: 8
Last. Marzieh SalehiH-Index: 19
view all 5 authors...
#1Henri HonkaH-Index: 8
#2Maria RayasH-Index: 5
Last. Marzieh SalehiH-Index: 19
view all 5 authors...
#1Xi ChenH-Index: 121
#2Marcel FourcaudotH-Index: 9
Last. Devjit TripathyH-Index: 45
view all 5 authors...
Although the effect of glucagon on glucose metabolism has been well characterized, its effect on adipose tissue and lipid metabolism in humans in vivo has been poorly studied with controversial results. We examined the effect of short-term hyperglucagonemia on adipocyte metabolism in 8 healthy normal glucose tolerant subjects (5M/3F, age=35±5, BMI = 24±1) who received a 12-hour (6PM to 6AM) glucagon infusion (6ng/kg/min) with 14C-glycerol infusion; subcutaneous abdominal adipose tissue biopsy wa...